|Mr. Scott William Drake||Pres, CEO & Director||1.23M||N/A||1968|
|Dr. James F. Dempsey||Chief Scientific Officer||468.31k||1.16M||1971|
|Mr. Zachary William Stassen||Chief Financial Officer||N/A||N/A||N/A|
|Ms. Michaella Gallina||Sr. Director of Investor Relations & Communications||N/A||N/A||N/A|
|Mr. Robert S. McCormack||Sr. VP, Gen. Counsel & Corp. Sec.||N/A||N/A||N/A|
|Karen Hackstaff||VP of Marketing||N/A||N/A||N/A|
|Mr. Robert Michael Fuchs||Chief HR Officer||N/A||N/A||1967|
|Dr. Martin Fuss||Chief Medical Officer||N/A||N/A||N/A|
ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. It has operations in the United States, France, Germany, Taiwan, the United Kingdom, and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.
ViewRay, Inc.’s ISS Governance QualityScore as of April 1, 2021 is 9. The pillar scores are Audit: 4; Board: 6; Shareholder Rights: 8; Compensation: 10.